Your browser is no longer supported. Please, upgrade your browser.
Settings
VBLT Vascular Biogenics Ltd. daily Stock Chart
VBLT [NASD]
Vascular Biogenics Ltd.
Index- P/E- EPS (ttm)-0.40 Insider Own26.60% Shs Outstand36.53M Perf Week-2.50%
Market Cap42.74M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float26.34M Perf Month-7.87%
Income-11.50M PEG- EPS next Q-0.19 Inst Own38.00% Short Float0.97% Perf Quarter-24.52%
Sales14.20M P/S3.01 EPS this Y42.30% Inst Trans1.49% Short Ratio1.81 Perf Half Y-56.67%
Book/sh2.03 P/B0.58 EPS next Y- ROA-19.90% Target Price3.00 Perf Year-83.17%
Cash/sh1.60 P/C0.73 EPS next 5Y- ROE-23.20% 52W Range1.08 - 8.75 Perf YTD-83.52%
Dividend- P/FCF- EPS past 5Y10.90% ROI-19.10% 52W High-86.99% Beta-1.26
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin96.60% 52W Low5.37% ATR0.08
Employees37 Current Ratio10.40 Sales Q/Q- Oper. Margin- RSI (14)41.40 Volatility7.26% 6.83%
OptionableYes Debt/Eq0.02 EPS Q/Q25.50% Profit Margin-80.70% Rel Volume0.13 Prev Close1.17
ShortableYes LT Debt/Eq0.01 EarningsNov 20 BMO Payout- Avg Volume140.96K Price1.14
Recom2.50 SMA20-2.69% SMA50-13.40% SMA200-43.17% Volume1,112 Change-2.74%
Mar-09-18Downgrade Chardan Capital Markets Buy → Neutral $25 → $3
Mar-08-18Downgrade Piper Jaffray Overweight → Neutral
Mar-08-18Downgrade H.C. Wainwright Buy → Neutral $3
Nov-06-17Reiterated Chardan Capital Markets Buy $20 → $25
Jun-28-16Initiated H.C. Wainwright Buy $11
Nov-09-15Initiated Piper Jaffray Overweight
Oct-23-15Reiterated Chardan Capital Markets Buy $25 → $27.50
Sep-28-15Reiterated ROTH Capital Buy $13 → $22
Sep-22-15Initiated Chardan Capital Markets Buy $25
Sep-21-15Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-22-15Initiated ROTH Capital Buy $13
Nov-21-18 09:28AM  Edited Transcript of VBLT earnings conference call or presentation 20-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
08:00AM  VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28 GlobeNewswire
Nov-20-18 08:15AM  Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:07AM  Vascular Biogenics: 3Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces Third Quarter 2018 Financial Results GlobeNewswire
Nov-16-18 07:00AM  VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting GlobeNewswire
Nov-13-18 07:00AM  VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20 GlobeNewswire
Oct-23-18 08:00AM  Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033 GlobeNewswire
Oct-11-18 07:00AM  Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis GlobeNewswire -7.74%
Sep-17-18 08:00AM  VBL Therapeutics to Present at Upcoming Conferences in October GlobeNewswire
Aug-30-18 07:00AM  VBL Therapeutics Announces Publication of Positive New Data on its Lecinoxoid Drug Candidates for the Treatment of Renal Fibrosis GlobeNewswire
Aug-17-18 07:34AM  Edited Transcript of VBLT earnings conference call or presentation 16-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga
08:15AM  Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:09AM  Vascular Biogenics: 2Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces Second Quarter 2018 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16 GlobeNewswire
Jul-10-18 08:00AM  Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy GlobeNewswire
Jun-27-18 04:01PM  VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering GlobeNewswire
Jun-26-18 08:57AM  VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -8.82%
Jun-20-18 07:05AM  Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-07-18 08:10AM  Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics ACCESSWIRE -13.33%
Jun-06-18 08:38AM  Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate Benzinga +39.53%
Jun-05-18 04:01PM  VBL Therapeutics Presents Positive Data on its MOSPD2 Platform Technology in Oncology and Inflammation at BIO 2018 GlobeNewswire
May-24-18 08:00AM  VBL Therapeutics to Present at Upcoming Conferences in June GlobeNewswire
May-18-18 08:31PM  Edited Transcript of VBLT earnings conference call or presentation 17-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-17-18 07:11AM  Vascular Biogenics: 1Q Earnings Snapshot Associated Press
07:00AM  VBL Therapeutics Announces First Quarter 2018 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
May-07-18 09:00AM  VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15 GlobeNewswire
May-01-18 08:00AM  VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17 GlobeNewswire
Apr-27-18 08:44AM  Vascular Biogenics (VBLT) Enters Oversold Territory Zacks
Apr-16-18 09:00AM  VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR GlobeNewswire -6.25%
Apr-12-18 08:52AM  Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options Zacks
Apr-10-18 08:00AM  VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16 GlobeNewswire +7.14%
Apr-09-18 08:00AM  VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority GlobeNewswire
Mar-15-18 06:31PM  Edited Transcript of VBLT earnings conference call or presentation 15-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
07:15AM  VBL Therapeutics Announces Year End 2017 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Mar-09-18 08:00AM  VBL Therapeutics to Report Fiscal 2017 Results on March 15 GlobeNewswire
Mar-08-18 09:00AM  Vascular Biogenics' stock plummets after brain cancer treatment trial fails MarketWatch -61.03%
06:00AM  VBL Therapeutics Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma GlobeNewswire
Feb-08-18 07:00AM  VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan GlobeNewswire
Jan-25-18 01:53PM  Does Vascular Biogenics Ltds (NASDAQ:VBLT) CEO Pay Compared Well With Peers? Simply Wall St.
Jan-04-18 05:10PM  Vascular Biogenics Ltd (NASDAQ:VBLT): Is Healthcare An Attractive Sector Play? Simply Wall St. +9.63%
Jan-03-18 07:05AM  VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors GlobeNewswire
Jan-02-18 08:30AM  Implied Volatility Surging for Vascular Biogenics (VBLT) Stock Options Zacks
Dec-27-17 07:00AM  VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc. GlobeNewswire
Dec-18-17 08:41AM  What Falling Estimates & Price Mean for Vascular Biogenics (VBLT) Zacks
08:28AM  New Biomarker Data Supports Direct Link between VB-111s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients GlobeNewswire
Nov-21-17 08:00AM  VBL Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-17-17 11:55AM  Why Vascular Biogenics Ltd. Is Tanking Today Motley Fool -23.89%
10:36AM  Heres Why Vascular Biogenics Ltd (VBLT) Stock Is Slumping Today SmarterAnalyst
09:00AM  VBL Therapeutics Prices  2.5 Million Ordinary Share Offering GlobeNewswire
Nov-16-17 04:01PM  VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares GlobeNewswire +17.26%
Nov-15-17 03:04AM  Edited Transcript of VBLT earnings conference call or presentation 14-Nov-17 1:30pm GMT Thomson Reuters StreetEvents -11.78%
Nov-14-17 07:23AM  Vascular Biogenics reports 3Q loss Associated Press +10.13%
07:00AM  VBL Therapeutics Announces Third Quarter 2017 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Nov-13-17 07:28PM  Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)? Simply Wall St.
Nov-09-17 08:00AM  VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18 GlobeNewswire
Nov-07-17 10:29AM  VBL Therapeutics to Report Third Quarter 2017 Results on November 14 GlobeNewswire +5.43%
Nov-06-17 07:00AM  VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan GlobeNewswire
Oct-23-17 08:05AM  VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters GlobeNewswire
Oct-20-17 07:00AM  VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe GlobeNewswire
Oct-02-17 07:00AM  VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM GlobeNewswire
Sep-28-17 07:00AM  VBL Therapeutics to Present at the Chardan Gene Therapy Conference GlobeNewswire
Sep-14-17 08:00AM  VBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New York GlobeNewswire
Aug-28-17 08:00AM  VBL Therapeutics to Present at the Rodman & Renshaw Global Investment Conference in New York on September 10-12, 2017 GlobeNewswire
Aug-16-17 08:30AM  Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3% Zacks
Aug-15-17 12:33PM  Edited Transcript of VBLT earnings conference call or presentation 14-Aug-17 12:30pm GMT Thomson Reuters StreetEvents +5.38%
Aug-14-17 10:21PM  Vascular Biogenics reports 2Q loss Associated Press +12.05%
07:00AM  VBL Therapeutics Announces Second Quarter 2017 Financial Results GlobeNewswire
06:00AM  Investor Network: Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Aug-02-17 08:00AM  VBL Therapeutics to Report Second Quarter 2017 Results on August 14 GlobeNewswire
Jun-19-17 08:00AM  VBL Therapeutics Provides Update on Long-Term Survival in Phase 2 Trials of Patients with Multiple Tumor Types GlobeNewswire +9.89%
Jun-15-17 07:00AM  VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer GlobeNewswire
Jun-14-17 08:00AM  VBL Therapeutics to Present at Upcoming June Conferences GlobeNewswire
Jun-08-17 07:00AM  VBL Therapeutics Awarded $2.5 Million Grant by the Israel Innovation Authority GlobeNewswire
Jun-05-17 07:30AM  New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM GlobeNewswire
May-15-17 07:20AM  Vascular Biogenics reports 1Q loss Associated Press
07:15AM  VBL Therapeutics Announces First Quarter 2017 Financial Results GlobeNewswire
07:00AM  Investor Network: Vascular Biogenics Ltd. to Host Earnings Call Accesswire
May-11-17 07:00AM  VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting GlobeNewswire
May-03-17 08:00AM  VBL Therapeutics to Report First Quarter 2017 Results on May 15 GlobeNewswire
Apr-25-17 07:00AM  VBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 Conferences GlobeNewswire
Apr-24-17 04:21PM  3 Different Companies, 3 Different Approaches to Tumors GuruFocus.com
Apr-20-17 04:01PM  VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM GlobeNewswire
Apr-04-17 07:00AM  VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target GlobeNewswire
07:00AM  VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
Apr-03-17 07:00AM  VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH GlobeNewswire
Mar-30-17 01:04PM  VASCULAR BIOGENICS LTD. Financials
Mar-28-17 07:00AM  VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference GlobeNewswire
Mar-27-17 07:30PM  Edited Transcript of VBLT earnings conference call or presentation 27-Mar-17 12:30pm GMT Thomson Reuters StreetEvents
07:30PM  Edited Transcript of VBLT earnings conference call or presentation 27-Mar-17 12:30pm GMT
08:30AM  Vascular Biogenics Ltd Earnings Call scheduled for 8:30 am ET today
07:30AM  VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Vascular Biogenics Ltd Earnings Release - Before Market Open
Mar-23-17 07:00AM  VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology GlobeNewswire +23.33%
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.